Drug Profile


Alternative Names: PNU 95666; U 95666

Latest Information Update: 15 Nov 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antiparkinsonians; Anxiolytics; Neuroprotectants
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 1A receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 15 Nov 2005 Data from preclinical studies have been added to the Parkinson's Disease and Movement Disorders pharmacodynamics section ,
  • 23 Jul 2004 Discontinued - Phase-II for Parkinson's disease in Japan (unspecified route)
  • 23 Jul 2004 Discontinued - Phase-III for Parkinson's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top